Announcement • Jul 14

Petvivo Holdings Publishes Peer-Reviewed Clinical Study Evaluating Spryng with Osteocushion Technology in Veterinary Record

PetVivo Holdings, Inc. in cooperation with its wholly-owned subsidiaries PetVivo Animal Health, Inc., Cosmeta Corp. and PetVivo AI, Inc. announced the publication of a peer-reviewed clinical study evaluating Spryng® with OsteoCushion® Technology in the peer-reviewed journal Veterinary Record. The study, entitled "Short-term outcomes following intra-articular biomaterial injection for pain secondary to stifle osteoarthritis and suspected cranial cruciate ligament injury in dogs," evaluated the use of Spryng®, PetVivo's proprietary collagen-elastin hydrogel microparticulate veterinary medical device, in dogs diagnosed with suspected cranial cruciate disease (CCD) and stifle osteoarthritis (OA). The prospective proof-of-concept study enrolled 40 client-owned dogs diagnosed with unilateral suspected cranial cruciate disease and osteoarthritis. Each dog received a single intra-articular injection of the collagen-elastin hydrogel microparticulate biomaterial and was evaluated over an 84-day period using serial clinical examinations, the modified Glasgow Composite Pain Scale (mGCPS), clinician assessments, and owner-reported outcome measures. 55% of enrolled dogs achieved at least a 25% improvement in the study's primary endpoint, the modified Glasgow Composite Pain Scale (mGCPS). Statistically significant improvements were observed across all additional subjective clinician- and owner-assessed outcome measures during the study period. The investigators concluded that the collagen-elastin hydrogel microparticulate biomaterial demonstrated feasibility for use in dogs with suspected cranial cruciate disease and stifle osteoarthritis within the subjective parameters evaluated, while noting that further studies utilizing objective outcome measures are warranted. The statistically significant improvements observed across multiple clinician- and owner-assessed outcome measures provide encouraging support for continued evaluation of Spryng® as an innovative treatment option for dogs suffering from osteoarthritis associated with cranial cruciate disease. The study was funded by PetVivo Holdings, Inc. and conducted by the participating investigators. The findings were subsequently evaluated and accepted for publication through the independent peer-review process of Veterinary Record. Publication in Veterinary Record, the official journal of the British Veterinary Association and one of the world's leading peer-reviewed veterinary journals, reflects the growing scientific interest in evaluating innovative biomaterial technologies for the management of osteoarthritis and other orthopedic conditions in companion animals. The study was conducted by a multi-center team of board-certified veterinary surgeons and specialists from leading veterinary referral hospitals throughout the United States, including Ethos Veterinary Health, Bridger Veterinary Specialists, Wisconsin Veterinary Referral Center, Bulger Veterinary Hospital, and Veterinary Specialty Hospital San Diego. The collaboration among multiple specialty centers underscores the broad clinical interest in evaluating innovative treatment options for canine osteoarthritis and cranial cruciate ligament disease. With this publication, PetVivo now has three peer-reviewed scientific publications evaluating Spryng® with OsteoCushion® Technology, further expanding the published body of scientific evidence supporting the Company's proprietary biomaterial platform. Spryng® with OsteoCushion® Technology is a proprietary intra-articular veterinary medical device comprised of sterilized extracellular matrix microparticles derived from natural collagen and elastin. The technology is designed to provide cushioning and structural support within the joint while helping veterinarians manage pain and lameness associated with non-infectious joint conditions in companion animals. PetVivo continues to expand the body of clinical evidence supporting Spryng®, the Company remains committed to collaborating with leading veterinary specialists and academic institutions to further evaluate the technology across additional orthopedic indications and clinical settings.

PetVivo Holdings, Inc. Stock Price

PETV Share Price Performance

PETV Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

PetVivo Holdings, Inc. Key Details

About PETV

Recent PETV News & Updates

PetVivo Holdings, Inc. to Report Q1, 2027 Results on Aug 14, 2026

Petvivo Holdings Publishes Peer-Reviewed Clinical Study Evaluating Spryng with Osteocushion Technology in Veterinary Record

PetVivo Expands with PBM Acquisition Gains Health Canada Approval and Launches AI Platform

Recent updates

PetVivo Holdings, Inc. Competitors

BioScience Health Innovations

DarioHealth

Daxor

Outset Medical